Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744815 | 0.82 | ESR1 (0.43) | MAPTL3MBTL1TDP1LMNAMEN1 | |
| SCHEMBL26998818 | 0.79 | MAPT (0.37) | MAPTL3MBTL1CCR1CCR8TDP1 | |
| SCHEMBL9732129 | 0.79 | MAPT (0.61) | MAPTL3MBTL1LMNAKMT2APOLB | |
| SCHEMBL29410744 | 0.79 | MAPT (0.61) | MAPTL3MBTL1LMNAKMT2APOLB | |
| SCHEMBL6844940 | 0.77 | MAPT (0.37) | MAPTL3MBTL1CCR1CCR8TDP1 | |
| SCHEMBL313086 | 0.77 | ALDH1A1 (0.42) | MAPTNPC1ALDH1A1KDM4EHSP90AA1 | |
| SCHEMBL11099839 | 0.76 | MAPT (0.35) | MAPTL3MBTL1CCR1CCR8CYP2A6 | |
| SCHEMBL26999488 | 0.75 | ALK (0.33) | CYP2A6POLBCYP3A4 | |
| SCHEMBL26999126 | 0.75 | CCR1 (0.39) | MAPTL3MBTL1CCR1CCR8CYP2A6 | |
| SCHEMBL26998833 | 0.75 | KDM4E (0.40) | MAPTL3MBTL1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| EP-4486734-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137112-A | Quinoline cGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240002346-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-01-04 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208452-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116234802-A | Quinoline CGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2022051634-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002346-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, SSB, NT5C2 | MAPT 4745/4885L3MBTL1 3793/4885CCR1 1450/4885 |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MAPT 3235/4885L3MBTL1 4285/4885CCR1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.